CrystalGenomics beats tough market to raise $20mn in new funding
This article was originally published in Scrip
Corporate fundraising may have its challenges in the current economic environment, but it seems that the right company and the right pipeline can still attract solid investor interest, at least in South Korea.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.